XOMA to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
Forward-Looking Statements/Explanatory Notes
Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the potential of XOMA’s portfolio of partnered programs and licensed technologies generating substantial milestone and royalty proceeds over time. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; we may not be successful in entering into out-license agreements for our product candidates; if our therapeutic product candidates do not receive regulatory approval, our third-party licensees will not be able to manufacture and market them. Other potential risks to
EXPLANATORY NOTE: All references to “portfolio” in this press release are to milestone and/or royalty rights associated with drug products in development. All references to “assets” in this presentation are to milestone and/or royalty rights associated with individual drug products in development.
Oratorium Group, LLC
KV Consulting & Management
Source: XOMA Corporation